Dramatic response of metaplastic breast cancer to chemo-immunotherapy
Sylvia Adams, Sylvia Adams
Abstract
Frequent overexpression of programmed death-ligand 1 has recently been demonstrated in metaplastic breast cancer, which is a rare breast cancer subtype with limited treatment options. This report describes the clinical course of a patient with metastatic metaplastic breast cancer who had a remarkable response to anti-programmed death-1 therapy with pembrolizumab in combination with nab-paclitaxel. Tissue correlates are presented including tumor-infiltrating lymphocytes and high-programmed death-ligand 1 expression in the tumor.
Conflict of interest statement
The authors declare no conflict of interest.
Figures
References
- Weigelt B, Eberle C, Cowell CF, Ng CK, Reis-Filho JS. Metaplastic breast carcinoma: more than a special type. Nat. Rev. Cancer. 2014;14:147–148. doi: 10.1038/nrc3637.
- Nelson RA, Guye ML, Luu T, Lai LL. Survival outcomes of metaplastic breast cancer patients: results from a US population-based analysis. Ann. Surg. Oncol. 2015;22:24–31. doi: 10.1245/s10434-014-3890-4.
- Rayson D, Adjei AA, Suman VJ, Wold LE, Ingle JN. Metaplastic breast cancer: prognosis and response to systemic therapy. Ann. Oncol. 1999;10:413–419. doi: 10.1023/A:1008329910362.
- Moulder S, et al. Inhibition of the phosphoinositide 3-kinase pathway for the treatment of patients with metastatic metaplastic breast cancer. Ann. Oncol. 2015;26:1346–1352.
- Joneja, U. et al. Comprehensive profiling of metaplastic breast carcinomas reveals frequent overexpression of programmed death-ligand 1. J. Clin. Pathol. doi:10.1136/jclinpath-2016-203874 (2016).
- Ping Z, Siegal GP, Almeida JS, Schnitt SJ, Shen D. Mining genome sequencing data to identify the genomic features linked to breast cancer histopathology. J.Path. Inform. 2014;5:3. doi: 10.4103/2153-3539.126147.
- Mittendorf EA, et al. PD-L1 expression in triple-negative breast cancer. Cancer Immunol. Res. 2014;2:361–370. doi: 10.1158/2326-6066.CIR-13-0127.
- Loi S, et al. RAS/MAPK activation is associated with reduced tumor-infiltrating lymphocytes in triple-negative breast cancer: therapeutic cooperation between MEK and PD-1/PD-L1 immune checkpoint inhibitors. Clin. Cancer Res. 2016;22:1499–1509. doi: 10.1158/1078-0432.CCR-15-1125.
- Barrett MT, et al. Genomic amplification of 9p24.1 targeting JAK2, PD-L1, and PD-L2 is enriched in high-risk triple negative breast cancer. Oncotarget. 2015;6:26483–26493. doi: 10.18632/oncotarget.4494.
- Alsuliman A, et al. Bidirectional crosstalk between PD-L1 expression and epithelial to mesenchymal transition: significance in claudin-low breast cancer cells. Mol. Cancer. 2015;14:149. doi: 10.1186/s12943-015-0421-2.
- Lien HC, et al. Molecular signatures of metaplastic carcinoma of the breast by large-scale transcriptional profiling: identification of genes potentially related to epithelial-mesenchymal transition. Oncogene. 2007;26:7859–7871. doi: 10.1038/sj.onc.1210593.
- Hennessy BT, et al. Characterization of a naturally occurring breast cancer subset enriched in epithelial-to-mesenchymal transition and stem cell characteristics. Cancer Res. 2009;69:4116–4124. doi: 10.1158/0008-5472.CAN-08-3441.
- Zhang Y, Toy KA, Kleer CG. Metaplastic breast carcinomas are enriched in markers of tumor-initiating cells and epithelial to mesenchymal transition. Mod. Pathol. 2012;25:178–184. doi: 10.1038/modpathol.2011.170.
Source: PubMed